<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02378376</url>
  </required_header>
  <id_info>
    <org_study_id>s55383</org_study_id>
    <nct_id>NCT02378376</nct_id>
  </id_info>
  <brief_title>In Vivo Quantification of Short Chain Fatty Acids Production in the Human Colon</brief_title>
  <official_title>In Vivo Quantification of Short Chain Fatty Acids Production in the Human Colon After Consumption of Different Cereal Fractions.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Katholieke Universiteit Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Katholieke Universiteit Leuven</source>
  <brief_summary>
    <textblock>
      During this project the amount of SCFA produced in the colon after consumption of 2 different
      13C-labelled wheat fiber fractions will be quantified.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quantification of acetate, propionate and butyrate production in the colon after consumption of each wheat derived fiber fraction</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Wheat derived fiber fraction 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arabinoxylan oligosaccharides</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Wheat derived fiber fraction 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dietary fiber enriched bran</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Arabinoxylan oligosaccharides</intervention_name>
    <arm_group_label>Wheat derived fiber fraction 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Dietary fiber enriched bran</intervention_name>
    <arm_group_label>Wheat derived fiber fraction 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Regular diet with 3 meals a day (minimal 5 times a week)

          -  BMI between 18.5 and 27 kg/m2

        Exclusion Criteria:

          -  Calorie restricted diet or other special diet during the study or during the last
             month prior to the study

          -  Antibiotics in the month prior to the study

          -  Former surgeries on the gastrointestinal tract, with the exception of an appendectomy

          -  use of the following types of medications with effects on the gastrointestinal tract
             during the last 2 weeks prior to the study (spasmolytica, anti-diarrhea,
             anti-constipation, probiotics)

          -  Chronic disease of the gastrointestinal tract such as Crohn's disease, ulcerative
             colitis, irritable bowel syndrome, chronic constipation, chronic frequent diarrhea,
             clinically relevant lactose intolerance

          -  Pregnancy, pregnancy desire or breastfeeding

          -  Diabetes (type 1 and 2)

          -  Blood donation in the past 3 months prior to the study

          -  Abnormal hemoglobin (Hb) levels in blood, men must have a Hb level between 14.0 and
             18.0 g / dL and women between 12.0 and 16.0 g / dL

          -  Participation in studies in the past year in which radiation was used.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 27, 2015</study_first_submitted>
  <study_first_submitted_qc>February 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2015</study_first_posted>
  <last_update_submitted>February 27, 2015</last_update_submitted>
  <last_update_submitted_qc>February 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Katholieke Universiteit Leuven</investigator_affiliation>
    <investigator_full_name>Kristin Verbeke</investigator_full_name>
    <investigator_title>Professor Kristin Verbeke</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

